These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 36408971)

  • 1. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
    Storandt MH; Jin Z; Mahipal A
    Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
    White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
    Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
    Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
    Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemigatinib: First Approval.
    Hoy SM
    Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
    Uson PLS; Bearss J; Babiker HM; Borad M
    Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
    Lindley A; Prager G; Bitzer M; Burn TC; Lihou CF; Croft E
    Cancer Res Treat; 2024 Jul; 56(3):847-855. PubMed ID: 38351684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
    Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
    Vogel A; Sahai V; Hollebecque A; Vaccaro GM; Melisi D; Al Rajabi RM; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Lihou CF; Zhen H; Veronese ML; Abou-Alfa GK
    ESMO Open; 2024 Jun; 9(6):103488. PubMed ID: 38838500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma.
    Hempel L; Lapa C; Dierks A; Gaumann A; Scheiber J; Veloso de Oliveira J; Philipp P; Oyarzun Laura C; Wesarg S; Robert S; Hempel D
    Ther Adv Med Oncol; 2022; 14():17588359221125096. PubMed ID: 36188486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.